SCHEMBL14025614

SCHEMBL14025614

CCN(CC)Cc1cccc(S(=O)(=O)N(C)Cc2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
HTT P42858 2/20 0.53
HPGD P15428 1/20 0.53
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.52
PKM P14618 1/20 0.52
MAPK1 P28482 1/20 0.52
HTR2C P28335 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HSD17B1 P14061 1/20 0.50
HSD17B2 P37059 1/20 0.50
POLB P06746 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ADRB2 P07550 1/20 0.48
MAPT P10636 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14025600 0.93 ALDH1A1 (0.50) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL4922953 0.87 ALDH1A1 (0.64) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL15676806 0.87 ALDH1A1 (0.57) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL1696927 0.84 ALDH1A1 (0.54) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL4745428 0.82 ALDH1A1 (0.56) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL407669 0.81 ALDH1A1 (0.73) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL14025625 0.81 PDE4A (0.54) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL18773879 0.81 ALDH1A1 (0.57) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL1692072 0.80 ALDH1A1 (0.53) ALDH1A1HTTHPGDLMNAKDM4E
SCHEMBL18970439 0.80 ALDH1A1 (0.53) ALDH1A1HTTHPGDLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
WO-2008109154-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS, INC. (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A ALDH1A1 423/4885HTT 4443/4885HPGD 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.